Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.20.

PYXS has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday.

Pyxis Oncology Trading Up 8.0 %

Shares of Pyxis Oncology stock opened at $1.21 on Friday. The firm has a market capitalization of $74.52 million, a PE ratio of -1.17 and a beta of 1.11. The firm’s 50 day moving average is $1.33 and its 200 day moving average is $2.35. Pyxis Oncology has a 1 year low of $0.99 and a 1 year high of $6.18.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The company had revenue of $16.15 million for the quarter. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently added to or reduced their stakes in the business. Ridgeback Capital Investments L.P. bought a new position in Pyxis Oncology in the fourth quarter worth approximately $560,000. ProShare Advisors LLC bought a new stake in Pyxis Oncology during the 4th quarter valued at $26,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pyxis Oncology during the fourth quarter worth $228,000. Millennium Management LLC lifted its stake in shares of Pyxis Oncology by 53.8% in the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock valued at $4,650,000 after buying an additional 1,043,228 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Pyxis Oncology by 57.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock valued at $939,000 after buying an additional 219,100 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.